Ack1

AIM-100 is a small molecule inhibitor of Ack1 with an IC50 of 24 nM.

KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.

GNF-7 is a potent type-II kinase Bcr-Abl inhibitor with IC50 of <5 nM, 61 nM, 122 nM, 136 nM, and 133 nM for M351T, T315I, E255 V, G250E, and c-Abl, respectively.

Ack1 Inhibitor 1 is a selective and orally active inhibitor of ACK1 kinase, exhibiting an IC50 value of 2.1 nM. This compound effectively inhibits the phosphorylation of ACK1, subsequently blocking the activation of downstream AKT signaling. Ack1 Inhibitor 1 demonstrates significant anti-tumor activity, making it a valuable tool for cancer research and therapeutic exploration.

(R)-9b is a potent inhibitor of ACK1 tyrosine kinase, exhibiting an IC50 value of 56 nM. This compound selectively targets ACK1 while also exhibiting inhibitory effects on JAK2 and Tyk2 kinases. (R)-9b is valuable for research into hormone-regulated cancers, including prostate and breast cancer, providing a tool for understanding ACK1's role in cancer progression and treatment.

Ack1 inhibitor 2 is a selective inhibitor of the Ack1 kinase, demonstrating an IC50 value of 0.46 μM. This compound effectively modulates the Ack1 signaling pathway, which plays a critical role in various cellular processes, including cell proliferation and survival. Ack1 inhibitor 2 is primarily utilized in research applications focused on cancer biology and molecular signaling studies.